J&J’s Intra-Cellular deal could signal more mega-mergers for 2025

Johnson & Johnson has agreed to acquire neuroscience specialist Intra-Cellular Therapies for almost $15 billion (£12 billion). This could be a harbinger for more billion-dollar deals this year, say analysts, as big companies look to replace revenues from impending patent expiries on blockbuster drugs. The trend will be helped by expectations that the new US administration could adopt a lighter touch to regulating mergers and acquisitions (M&A).